A Phase 3 interventional study of sitagliptin phosphate and Glimepiride in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 65 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-06-05.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 34th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2010, is one of 74 in phase 3, and was the 93rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 65 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 23 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 480 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 48th largest by enrollment of the 170 interventional ones that give a count, is one of 16 that started in 2010, is one of 86 in phase 3, and was the 108th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to determine if sitagliptin treatment is not inferior to that of glimepiride as measured by the change in baseline hemoglobin A1C (HbA1C) after 30 weeks of treatment, and if sitagliptin treatment results in a lower incidence of symptomatic hypoglycemia compared to that of glimepiride. The study will also evaluate if sitagliptin treatment, compared to glimepiride results in improvements in fasting plasma glucose (FPG) levels, and plasma lipid levels after 30 weeks of treatment. Participants will be randomized to either sitagliptin or glimepiride treatment after eligibility for study participation is determined during screening and washout study phases. Participants and study staff will not know to which treatment group they have been randomized (double-blind design). The duration of study participation will be up to 40 weeks (with 9 clinic visits). This will include a screening phase (Visit 1 to Visit 2) of 2 weeks maximum; a 6-week (Visits 2 to 3) oral antihyperglycemic agent (AHA) wash-out phase (for those who have been taking a AHA prior to the study); a placebo run-in phase (Visits 3 to 4), followed by up to 30 weeks of treatment with study medication.
The dose of sitagliptin will be 100 mg once daily (QD) or 50 mg QD based on the participant's estimated glomerular filtration rate (eGFR). The starting dose of glimepiride (1 mg QD) may be up-titrated as needed to optimize glycemic control over the first 18 weeks to a maximum dose of 6 mg/day, after which the dose will not be increased for the rest of the study (down-titration to avoid or control hypoglycemia is allowed).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sitagliptin phosphate 100 mg or 50 mg once daily (QD)
Drug: sitagliptin phosphate · Drug: Placebo to Glimepiride
Glimepiride 1-6 mg QD
Drug: Glimepiride · Drug: Placebo to Sitagliptin
Sitagliptin tablets, orally, at a dose of 100 mg or 50 mg QD for 30 weeks. The dose level to be administered will depend on the participant's estimated glomerular filtration rate (eGFR), calculated at Visit 3 and may be adjusted as medically indicated during the study.
Also known as: Januvia
Glimepiride tablets, orally, starting at a dose of 1 mg QD, which may be gradually increased, as needed, to maximum dose of 6 mg QD for 30 weeks. The dose may also be decreased as medically indicated during the study.
Also known as: Amaryl
Matching placebo tablets to sitagliptin to allow for blinding.
Matching placebo tablets to glimepiride to allow for blinding.
Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30
Participant whole blood samples were collected at baseline and Week 30 to determine the LS mean HbA1c change from baseline. HbA1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.
Time frame: Baseline and Week 30
Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30
Symptomatic hypoglycemia was defined as an episode with clinical symptoms attributed to hypoglycemia, without regard to glucose level. Participants were instructed to complete the Hypoglycemia Assessment Log (HAL) for any symptomatic episodes he or she believed represent hypoglycemia. If a fingerstick glucose was obtained before or shortly (i.e., within a few minutes) after treating, the value was recorded in the HAL. In addition, participants were instructed to record in the HAL any fingerstick glucose values ≤70 mg/dL (≤3.9 mmol/L) regardless of the presence of clinical symptoms.
Time frame: Up to Week 30
Number of Participants Experiencing An Adverse Event (AE)
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study treatment, whether or not considered related to the use of the treatment administered.
Time frame: Up to Week 30
Number of Participants Discontinuing Study Treatment Due to An AE
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study treatment, whether or not considered related to the use of the treatment administered.
Time frame: Up to Week 30
LS Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30
Plasma samples were collected from participants after an overnight fast at baseline and Week 30 to determine the mean change from baseline in participant FPG.
Time frame: Baseline and Week 30
Percentage of Participants With HbA1c <7.0% at Week 30
Participant whole blood samples were collected at Week 30 to determine the number of participants achieving HbA1c \<7.0% at Week 30. HbA1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.
Time frame: Week 30
Percentage of Participants With HbA1c <6.5% at Week 30
Participant whole blood samples were collected at Week 30 to determine the number of participants achieving HbA1c \<6.5% at Week 30. Hemoglobin A1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.
Time frame: Week 30
LS Mean Change From Baseline in Participant Body Weight at Week 30
Participants were only permitted to wear a drape gown and undergarments (no street clothes, no shoes or socks) for this evaluation. Body weight was measured after voiding (to the nearest 0.1 kg) and measurements were collected until 2 consecutive measurements did not differ by more than 0.2 kg from each other. Body weight measurements were evaluated using a standardized, calibrated digital scale and was reported in kilograms (kg) at baseline and Week 30.
Time frame: Baseline and Week 30
| Milestone | Sitagliptin | Glimepiride |
|---|---|---|
| Started | 241 | 239 |
| Completed | 204 | 200 |
| Not completed | 37 | 39 |
| Withdrew: Adverse event | 3 | 4 |
| Withdrew: Lack of efficacy | 7 | 2 |
| Withdrew: Lost to follow-up | 1 | 7 |
| Withdrew: Protocol violation | 1 | 5 |
| Withdrew: Withdrawal by subject | 15 | 11 |
| Withdrew: Non compliance | 0 | 1 |
| Withdrew: Physician decision | 5 | 4 |
| Withdrew: Hyperglycemia discontinuation criteria | 5 | 5 |
Participant whole blood samples were collected at baseline and Week 30 to determine the LS mean HbA1c change from baseline. HbA1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.
| Percentage of HbA1c | Sitagliptin | Glimepiride |
|---|---|---|
| Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30 | -0.32 ± 0.78 | -0.51 ± 0.89 |
Symptomatic hypoglycemia was defined as an episode with clinical symptoms attributed to hypoglycemia, without regard to glucose level. Participants were instructed to complete the Hypoglycemia Assessment Log (HAL) for any symptomatic episodes he or she believed represent hypoglycemia. If a fingerstick glucose was obtained before or shortly (i.e., within a few minutes) after treating, the value was recorded in the HAL. In addition, participants were instructed to record in the HAL any fingerstick glucose values ≤70 mg/dL (≤3.9 mmol/L) regardless of the presence of clinical symptoms.
| Participants | Sitagliptin | Glimepiride |
|---|---|---|
| Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30 | 2 | 11 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study treatment, whether or not considered related to the use of the treatment administered.
| Participants | Sitagliptin | Glimepiride |
|---|---|---|
| Number of Participants Experiencing An Adverse Event (AE) | 118 | 115 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study treatment, whether or not considered related to the use of the treatment administered.
| Participants | Sitagliptin | Glimepiride |
|---|---|---|
| Number of Participants Discontinuing Study Treatment Due to An AE | 3 | 4 |
Plasma samples were collected from participants after an overnight fast at baseline and Week 30 to determine the mean change from baseline in participant FPG.
| mg/dL | Sitagliptin | Glimepiride |
|---|---|---|
| LS Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30 | -14.5 ± 39.0 | -21.2 ± 39.1 |
Participant whole blood samples were collected at Week 30 to determine the number of participants achieving HbA1c \<7.0% at Week 30. HbA1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.
| Percentage of Participants | Sitagliptin | Glimepiride |
|---|---|---|
| Percentage of Participants With HbA1c <7.0% at Week 30 | 33.5 | 46.6 |
Participant whole blood samples were collected at Week 30 to determine the number of participants achieving HbA1c \<6.5% at Week 30. Hemoglobin A1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.
| Percentage of Participants | Sitagliptin | Glimepiride |
|---|---|---|
| Percentage of Participants With HbA1c <6.5% at Week 30 | 9.1 | 20.9 |
Participants were only permitted to wear a drape gown and undergarments (no street clothes, no shoes or socks) for this evaluation. Body weight was measured after voiding (to the nearest 0.1 kg) and measurements were collected until 2 consecutive measurements did not differ by more than 0.2 kg from each other. Body weight measurements were evaluated using a standardized, calibrated digital scale and was reported in kilograms (kg) at baseline and Week 30.
| kg | Sitagliptin | Glimepiride |
|---|---|---|
| LS Mean Change From Baseline in Participant Body Weight at Week 30 | 0.4 ± 3.2 | 1.1 ± 2.8 |
Collected over Up to Week 32.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin | — | 7/241 (2.9%) | 34/241 (14.1%) |
| Glimepiride | — | 6/236 (2.5%) | 40/236 (16.9%) |
| Event | Sitagliptin | Glimepiride |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/241 | 1/236 |
| Angina UnstableCardiac disorders | 0/241 | 1/236 |
| Cardiac Failure ChronicCardiac disorders | 0/241 | 1/236 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 0/241 | 1/236 |
| Nerve CompressionNervous system disorders | 0/241 | 1/236 |
| SyncopeNervous system disorders | 0/241 | 1/236 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/241 | 1/236 |
| Atrial FibrillationCardiac disorders | 1/241 | 0/236 |
| Inguinal HerniaGastrointestinal disorders | 1/241 | 0/236 |
| Lower Gastrointestinal HaemorrhageGastrointestinal disorders | 1/241 | 0/236 |
| Event | Sitagliptin | Glimepiride |
|---|---|---|
| NasopharyngitisInfections and infestations | 18/241 | 19/236 |
| HypoglycaemiaMetabolism and nutrition disorders | 3/241 | 15/236 |
| HyperglycaemiaMetabolism and nutrition disorders | 14/241 | 9/236 |
| Age, Continuous(years) | Sitagliptin | Glimepiride | Total |
|---|---|---|---|
| Mean | 70.7 ± 4.8 | 70.8 ± 4.9 | 70.7 ± 4.8 |
| Sex: Female, Male(Participants) | Sitagliptin | Glimepiride | Total |
|---|---|---|---|
| Female | 130 | 148 | 278 |
| Male | 111 | 91 | 202 |
| Hemoglobin A1c (HbA1c)(Percentage of HbA1c) | Sitagliptin | Glimepiride | Total |
|---|---|---|---|
| Mean | 7.78 ± 0.70 | 7.78 ± 0.67 | 7.78 ± 0.69 |
| Fasting Plasma Glucose (FPG)(mg/dL) | Sitagliptin | Glimepiride | Total |
|---|---|---|---|
| Mean | 168.4 ± 31.2 | 169.7 ± 35.5 | 169.0 ± 33.3 |
| Body Weight(kg) | Sitagliptin | Glimepiride | Total |
|---|---|---|---|
| Mean | 76.9 ± 15.1 | 75.4 ± 16.4 | 76.0 ± 15.6 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Aug 2010 to primary completion in Oct 2012, 26 months.
Results were first posted in Jun 2013, 7 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 26 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin